CADTH Canadian Drug Expert Committee recommendation. indication : treatment of neovascular (wet) age-related macular degeneration (nAMD). Brolucizumab (Beovu -- Novartis Pharmaceuticals Canada Inc.) :
Brolucizumab has a Health Canada indication for the treatment of nAMD. Brolucizumab is a humanized monoclonal single-chain Fv (scFv) antibody fragment directed against human VEGF. It is available as a single-use pre-filled syringe for intravitreal injection and the Health Canada-approved dose is 6...
Saved in:
| Online Access: |
Full text |
|---|---|
| Corporate Author: | |
| Format: | Electronic eBook |
| Language: | English |
| Published: |
Ottawa (ON) :
Canadian Agency for Drugs and Technologies in Health,
2020
|
| Edition: | Version: 1. |
| Series: | Common drug review clinical review report.
|
| Subjects: |
